BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24940615)

  • 1. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
    Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
    PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.
    Yiming L; Yunshan G; Bo M; Yu Z; Tao W; Gengfang L; Dexian F; Shiqian C; Jianli J; Juan T; Zhinan C
    Oncotarget; 2015 Dec; 6(39):42019-27. PubMed ID: 26503471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.
    Zhong C; Wu JD; Fang MM; Pu LY
    Tumour Biol; 2015 Sep; 36(10):7623-30. PubMed ID: 25921286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
    Qu H; Li R; Liu Z; Zhang J; Luo R
    Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
    Wu B; Sun C; Feng F; Ge M; Xia L
    J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.
    Zhang J; Gu Y; Liu X; Rao X; Huang G; Ouyang Y
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32696952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.
    Wang W; Chen Y; Deng J; Zhou J; Zhou Y; Wang S; Zhou J
    Tumour Biol; 2014 Oct; 35(10):9769-75. PubMed ID: 24973892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis.
    Xu YH; Zhang GB; Wang JM; Hu HC
    Saudi Med J; 2010 Sep; 31(9):980-6. PubMed ID: 20844808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.
    Chen E; Zeng Z; Bai B; Zhu J; Song Z
    Oncotarget; 2016 Aug; 7(35):56526-56539. PubMed ID: 27489355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
    Li X; Zhao H; Gu J; Zheng L
    Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.
    Liu X; Huang G; Zhang J; Zhang L; Liang Z
    PLoS One; 2020; 15(10):e0240321. PubMed ID: 33052949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
    Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
    Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
    Huang M; Zhu H; Feng J; Ni S; Huang J
    Dis Markers; 2015; 2015():986095. PubMed ID: 25691807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small nucleolar RNA signatures of lung tumor-initiating cells.
    Mannoor K; Shen J; Liao J; Liu Z; Jiang F
    Mol Cancer; 2014 May; 13():104. PubMed ID: 24886050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
    Yang SL; Ren QG; Wen L; Hu JL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry.
    Wu S; Yu L; Wang D; Zhou L; Cheng Z; Chai D; Ma L; Tao Y
    BMC Cancer; 2012 Nov; 12():535. PubMed ID: 23170850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review.
    Wen L; Chen XZ; Yang K; Chen ZX; Zhang B; Chen JP; Zhou ZG; Mo XM; Hu JK
    PLoS One; 2013; 8(3):e59154. PubMed ID: 23533603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.
    Luo Z; Wu RR; Lv L; Li P; Zhang LY; Hao QL; Li W
    Int J Clin Exp Pathol; 2014; 7(7):3632-46. PubMed ID: 25120740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.